Linganisha mbinu
Pitia mbinu ulizochagua bega kwa bega; safu zinazotofautiana zinaangaziwa.
| Jarida la Kliniki la Awamu ya II× | Uchambuzi wa Uhusiano wa Dozi-Majibu× | |
|---|---|---|
| Nyanja | Epidemiolojia | Epidemiolojia |
| Familia | Process / pipeline | Process / pipeline |
| Mwaka wa asili≠ | 1960s–1970s (formalised in US federal drug regulation) | Conceptual roots 16th century; modern epidemiological application mid-20th century |
| Mwanzilishi≠ | U.S. Food and Drug Administration / ICH E8 guidelines (institutionalised framework) | Paracelsus (conceptual foundation); formalized by John Snow and later Bradford Hill |
| Aina≠ | Interventional clinical study design | Quantitative analytical method |
| Chanzo asilia≠ | Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015). Fundamentals of Clinical Trials (5th ed.). Springer. ISBN: 978-3319185392 | Rothman, K. J., Greenland, S., & Lash, T. L. (2008). Modern Epidemiology (3rd ed.). Lippincott Williams & Wilkins. ISBN: 978-0781755641 |
| Majina mbadala | Phase 2 trial, Phase II study, early efficacy trial, proof-of-concept trial | exposure-response analysis, concentration-response modeling, dose-response modeling, DRA |
| Zinazohusiana≠ | 6 | 4 |
| Muhtasari≠ | A Phase II clinical trial is the second stage in the drug or intervention development pipeline, conducted after Phase I safety testing. Its primary goal is to assess whether the intervention shows preliminary efficacy signals in a relevant patient population at the dose established in Phase I, while continuing to characterise the safety and tolerability profile. Phase II trials are generally smaller than Phase III confirmatory trials and serve as critical go/no-go decision points before large-scale investment. | Dose-response analysis quantifies the relationship between the magnitude of an exposure (the dose) and the probability or rate of an outcome (the response). It is a core analytical strategy in epidemiology and toxicology, providing evidence that increasing exposure systematically increases — or decreases — the risk of disease. A demonstrated dose-response gradient is one of Bradford Hill's classic criteria supporting causal inference. |
| ScholarGateSeti ya data ↗ |
|
|